UCB SUBMITS NDA FOR RHINITIS TREATMENT

UCB has submitted a new drug application (NDA) to the FDA for Xyzal (levocetirizine dihydrochloride), a new prescription antihistamine for treatment of allergy symptoms.

UCB requested as part of the FDA application the following indications: seasonal allergic rhinitis, perennial allergic rhinitis and chronic idiopathic urticaria in adults and children 6 and older.

The drug was first launched in Europe in 2001 and is currently marketed in 49 countries.